Enriqueta Felip
MD, PhD
Head of Thoracic Cancer Unit
👥Biography 个人简介
Enriqueta Felip led the practice-changing IMpower010 trial establishing adjuvant atezolizumab after chemotherapy for resected PD-L1 positive stage II-IIIA NSCLC. Her work defined the first approved adjuvant checkpoint inhibitor in lung cancer. She continues to refine PD-L1 thresholds, patient selection, and sequencing with perioperative strategies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Enriqueta Felip 的研究动态
Follow Enriqueta Felip's research updates
留下邮箱，当我们发布与 Enriqueta Felip（Vall d'Hebron Institute of Oncology）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment